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Objectives 
The relevance of the SYNTAX score for the particular case of patients with acute ST-
segment elevation myocardial infarction (STEMI) undergoing primary percutaneous 
coronary intervention (PPCI)	  has previously only been studied in the setting of post 
hoc analysis of large prospective randomized clinical trials. A “real-life” population 
approach has never been explored before. 
The aim of this study was to evaluate the impact of the SYNTAX score for the 
prediction of the myocardial infarction size, estimated by the creatin-kinase (CK) 
peak value, using the SYNTAX score in patients treated with primary coronary 
intervention for acute ST-segment elevation myocardial infarction. 
Methods 
The primary endpoint of the study was myocardial infarction size as measured by the 
CK peak value. The SYNTAX score was calculated retrospectively in 253 
consecutive patients with acute ST-segment elevation myocardial infarction (STEMI) 
undergoing primary percutaneous coronary intervention (PPCI) in a large tertiary 
referral center in Switzerland, between January 2009 and June 2010. Linear 
regression analysis was performed to compare myocardial infarction size with the 
SYNTAX score. This same endpoint was then stratified according to SYNTAX score 
tertiles: low <22 (n=178), intermediate [22-32] (n=60), and high >=33 (n=15). 
Results 
There were no significant differences in terms of clinical characteristics between the 
three groups. When stratified according to the SYNTAX score tertiles, average CK 
peak values of 1985 (low<22), 3336 (intermediate [22-32]) and 3684 (high>=33) were 
obtained with a p-value <0.0001. Bartlett's test for equal variances between the three 
groups was 9.999 (p-value <0.0067). A moderate Pearson product-moment 
correlation coefficient (r=0.4074) with a high statistical significance level (p-value 
<0.0001) was found. The coefficient of determination (R^2=0.1660) showed that 
approximately 17% of the variation of CK peak value (myocardial infarction size) 
could be explained by the SYNTAX score, i.e. by the coronary disease complexity. 
 
Conclusion 
In an all-comers population, the SYNTAX score is an additional tool in predicting 
myocardial infarction size in patients treated with primary percutaneous coronary 
intervention (PPCI). The stratification of patients in different risk groups according to 
SYNTAX enables to identify a high-risk population that may warrant particular patient 
care. 
Introduction 
Optimal revascularization strategy in patients with coronary disease remains a 
disputed subject. Several risk scores have been designed and validated for patients 
presenting with ST-segment elevation myocardial infractions (STEMI) [1-5]. They are 
mainly patient-based, therefore do not take into account the lesion characteristics 
and their individual prediction ability is variable [6]. Though the SYNTAX score has 
primarily been developed to assess the risks of coronary revascularization (either 
percutaneous or surgical) by integrating the functional impact of coronary disease 
complexity using anatomic characteristics such as bifurcations, type of occlusions, 
thrombus, calcifications, tortuosities, bridgings, etc., visualized during coronary 
angiography [7,8]. This score has largely been validated [9-15] but was almost only 
limited to elective patients and tough its utility of risk stratifying patients with STEMI is 
not very well unknown [16]. 
The aim of our study was to evaluate the impact of the SYNTAX score for the 
prediction of the myocardial infarction size, estimated by the creatin-kinase (CK) 
peak value, using the SYNTAX score in patients treated with primary coronary 
intervention for acute ST-segment elevation myocardial infarction, in a well defined 
region of the French part of Switzerland and based on a real-life registry. 
 
Methods 
Patient population 
Between January 1st 2009 and June 30th 2010, 402 consecutive patients underwent 
PPCI for STEMI in a large tertiary referral center in Switzerland. This institution is the 
only site performing primary percutaneous coronary intervention (PPCI) in the region 
(approximately 700’000 inhabitants). Patients with “symptom-to-first-medical-contact” 
time longer than 12 hours, patients with a previous treatment by fibrinolysis or 
already hospitalized during their STEMI, patient with previous CABG or directly 
referred for CABG were excluded. We excluded as well those patients who died 
during the coronarography but before angioplasty. 345 patients were finally included 
(Figure 1). Coronary angiographies, laboratory values, clinical and demographic data 
were collected from hospital and catheter laboratory databases. All coronary lesions 
with a diameter stenosis >=50% in vessels >=1.5 mm were scored using the 
SYNTAX score algorithm. The online calculator version 2.11 (www.syntaxscore. 
com) was used. 
Study endpoint 
The endpoint of the study was myocardial infarction size by using the CK peak value, 
which is validated as a good quantitative assessment of the extent of myocardial 
infarction [17,18].  
Definition of STEMI 
STEMI was defined according to the universal definition of myocardial infarction of 
the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial 
Infarction [19]. 
Statistical Analysis 
GraphPad Prism software 5.0d was used to perform statistical analysis. Linear 
regression analysis was performed to compare myocardial infarction size with the 
SYNTAX score. The Pearson product-moment, with 95% confidence interval, two-
tailed p-value and the coefficient of determination have been calculated. This same 
endpoint was then stratified according to SYNTAX score tertiles: low <22 (n=178), 
intermediate [22-32] (n=60), and high >=33 (n=15). Bartlett's test for equal variances 
was subsequently calculated between the three groups. 
Ethical issues 
Our study complies with the Declaration of Helsinki regarding investigations in 
humans. It had been approved by the Institutional Ethics Committee.	  
 
Results 
Baseline demographics and clinical outcome 
Characteristics of the patients enrolled in this study are summarized in Table 1. 
Median age was 62,0 years. 72,2% of patients was male. There was no significant 
differences in terms of clinical characteristics between the three groups. Mean peak 
CK value was 2406 U/L and left ventricular ejection fraction (LVEF) assessed by 
echocardiography at discharge was 47%. Myocardial infarction localization is 
summarized in Table 2.  At 1-year follow-up, all cause mortality rate was 5.80%. 
 
Infarction size prediction with the SYNTAX score 
When stratified according to the SYNTAX score tertiles (Figure 2), average CK peak 
values of 1985 U/L (low<22), 3336 U/L (intermediate [22-32]) and 3684 U/L 
(high>=33) were obtained with a p-value <0.0001. Bartlett's test for equal variances 
between the three groups was 9.999 (p-value <0.0067). A moderate Pearson 
product-moment correlation coefficient (r=0.4074) with a high statistical significance 
level (p-value <0.0001) was found (Figure 3). The coefficient of determination 
(R^2=0.1660) shows that 16.6% of the variation of CK peak value (myocardial 
infarction size) can be explained by the SYNTAX score, i.e. by the coronary disease 
complexity. 
 
Discussion 
The present study showed that a global risk assessment for patients with STEMI 
undergoing PPCI has to integrate the anatomical and functional dimension of 
coronary disease, by means of the SYNTAX score, and not only the patient-based 
characteristics, even though these are necessary and important variables. 
Prior studies evaluating the relevance of the SYNTAX score for the particular case of 
patients with acute STEMI undergoing primary percutaneous coronary intervention 
(PPCI) [15-16,20] are substudies based on large prospective randomized trials like 
STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus 
Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) [21], 
MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban 
Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute 
Myocardial Infarction Study) [22], SIRTAX (Sirolimus-eluting and paclitaxel-eluting 
stents for coronary revascularization) [23] and RESOLUTE (A Randomized 
Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for 
Percutaneous Coronary Intervention) [24]. The largest study pools seven coronary 
stent trials, including those already cited, and “confirms the consistent ability of the 
SYNTAX score to identify patients who are at highest risk of adverse events” [25]. 
Except for two studies based on the same population [26,27], a “real-life” population 
approach has never been explored before. There are limited to highly selected 
randomized controlled trials patients. 
Our results are concordant with the previous studies [14-16,20,25,26]. The SYNTAX 
score may allow prospective risk stratification of patients undergoing PPCI [14,26] 
and is able to stratify risk amongst an all-comers population [20]. 
We established the ability of the SYNTAX score in stratifying infarction size, as in the 
current study in an all-comers population presenting with STEMI and subsequently 
treated with PPCI. However, and as already mentioned in prior studies [16,20], 
improvements can be made with the inclusion of clinical variables. Farooq et al. [28-
30] highlighted that “while prognostically useful in risk-stratifying patients […], in itself 
appears to carry important information on clinical comorbidity and outcomes for the 
individual patient. However, […] the incremental value of adding clinical variables to 
the SYNTAX score […] will ultimately prove to be more clinically useful compared 
with the SYNTAX score alone” [28]. They also noticed how “novel concepts such as 
the Functional Syntax score, especially if this can be performed noninvasively, and 
the patient empowered risk-benefit trade-off are all further areas in current 
development in which additional clinically relevant information may become 
available” [29]. We share this point of view. 
The present study has several limitations. This is a retrospective observation in a 
limited number of patients. However it has the advantage of being consecutive, 
homogeneous, including all patients with STEMI undergoing PPCI in a defined period 
of time and in well-defined region.  Furthermore the hospital where this study was 
performed is the only center for PPCI of STEMI in this region of the French part of 
Switzerland. 
 
Conclusion 
In conclusion, the syntax score emerges as a useful tool in predicting infarct size 
during PPCI for STEMI.  Further research should probably focus on developing even 
more accurate risks scores taking also into account clinical scores. 
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Table 1 
Table 1. Baseline demographics & outcome  SYNTAX tertiles  
Gender and age  Low (%) Intermediate (%) High (%) 
Male gender (n, %) 249 (72.2) 73.0 70.0 46.7 
 
Age (mean ± SD) 61.96 ± 12.8 63.3 63.9 67.5 
 
      
Cardiovascular Risk Factors (%)    
Dyslipidemia 52.0 52.8 62.7 50.0 
Diabetes 24.0 21.3 28.8 35.7 
Hypertension 48.8 41.1 44.1 71.4 
Family history 13.2 12.4 13.6 14.3 
Obesity 25.4 23.0 23.7 42.9 
Smoking 53.5 55.6 55.9 28.6 
       
Previous cardiovascular history (%)    
Prior PCI or MI 11.9 10.1 15.0 6.7 
     
Outcome  Low Intermediate High 
Peak CK (mean ± SD) 2406 ±  1905 
 
1985 3336 3684 
LVEF (mean % ± SD) 47.19 ± 11.85 50.0 44.4 41.4 
 
 
 
Table 2 
Table 2. Myocardial infarction localization 
Inferior (%) 32.2 
Anterior (%) 46.1 
Posterior  (%) 
 
 
1.7 
Infero-posterior (%) 9.6 
Lateral (%) 2.6 
Antero-latero-posterior (%) 0.6 
Infero-lateral (%) 4.6 
Postero-lateral (%) 0.3 
Undefined (%) 2.3 
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